Lanadelumab

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hereditary Angioedema4 trials

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT05460325·20 enrolled

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

Completed·Takeda·Phase 3·NCT04070326·21 enrolled

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No longer available·Takeda··NCT04583007

Show 1 more trial

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT04180163·12 enrolled

Angioedema3 trials

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Completed·Takeda·Phase 3·NCT04206605·77 enrolled

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed·Takeda·Phase 3·NCT04444895·73 enrolled

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Recruiting·—·Phase 4·NCT06818474·5 enrolled

COVID-192 trials

Lanadelumab for Treatment of COVID-19 Disease

Completed·RRadboud University Medical Center·Phase 1/2·NCT04422509·43 enrolled

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Completed·Amgen·Phase 3·NCT04590586·515 enrolled

Pneumonia1 trial

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

Withdrawn·Takeda·Phase 1·NCT04460105

Intravenous1 trial

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Completed·Takeda·Phase 1·NCT04503603·12 enrolled

5 more indications

Injury1 trial

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Active, not recruiting·—·Phase 1·NCT04848272·48 enrolled

LAM1 trial

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

Unknown status·—·Phase 2·NCT04278885·4 enrolled

Adult Subject1 trial

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

Completed·Takeda·Phase 1·NCT03401671·32 enrolled

Hemodialysis Complication1 trial

Prevention of Dialysis-Induced Hypotension by Inhibiting Plasma Kallikrein

Completed·VVanderbilt University Medical Center·Phase 2·NCT05297786·28 enrolled

Hereditary Angioedema (HAE)1 trial

Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 mg Syringe for Hereditary Angioedema With Long-term Administration

Active, not recruiting·Takeda··NCT05397431·155 enrolled

Details

Drug Info

Related News